Jazz Pharmaceuticals plc (JAZZ)Healthcare | Biotechnology | Dublin, Ireland | NasdaqGS
210.23 USD
-4.19
(-1.954%) ⇩
(Oct. 16, 2026, 4 p.m.
EDT)
After hours: 210.23 |
Hot Take ↕ | Oct. 3, 2026, 2:52 a.m. EDT
The long-term investment case is compelling, driven by robust revenue growth of 15.5 percent and a return on equity of 22 percent, alongside a forward price-to-earnings ratio of 9.1 that suggests the market is pricing in significant expansion. The nine-year price trajectory shows a cumulative gain of 14.4 percent, with the most recent annual performance surging 28.5 percent, indicating a strong recovery from previous headwinds. However, the short-term outlook lacks a clear directional edge; the stock trades below its 50-day moving average, and statistical models hint at slight downside pressure, creating a technical ceiling despite the solid 200-day support. Furthermore, there is no dividend income available to investors. While the fundamentals are exceptional and the valuation is attractive, the immediate technical setup remains mixed, making this a hold for accumulation rather than a momentum play. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.053630 |
| AutoETS | 0.055888 |
| AutoTheta | 0.078855 |
| AutoARIMA | 0.095812 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 14.46 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.168 |
| Excess Kurtosis | 0.52 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 91.828 |
| Revenue per Share | 74.598 |
| Market Cap | 13,646,991,360 |
| Trailing P/E | 14.41 |
| Forward P/E | 8.07 |
| Beta | 0.37 |
| Profit Margins | 20.45% |
| Website | https://www.jazzpharma.com |
As of Oct. 3, 2026, 2:52 a.m. EDT: Speculators are positioning for upside potential with call option open interest concentrated at the 250, 280, and 300 strike levels, while put buyers are hedging downside risk primarily around the 230 strike. Implied volatility remains elevated across expirations, suggesting expectations for significant price movement.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.55899143 |
| Address1 | Waterloo Exchange |
| Address2 | Fifth Floor Waterloo Road Dublin 4 |
| All Time High | 266.38 |
| All Time Low | 0.52 |
| Ask | 227.71 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.5 - Strong Buy |
| Average Daily Volume10 Day | 880,920 |
| Average Daily Volume3 Month | 882,568 |
| Average Volume | 882,568 |
| Average Volume10Days | 880,920 |
| Beta | 0.369 |
| Bid | 195.78 |
| Bid Size | 2 |
| Board Risk | 4 |
| Book Value | 74.1 |
| City | Dublin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | Ireland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 210.23 |
| Current Ratio | 1.779 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 214.775 |
| Day Low | 208.185 |
| Debt To Equity | 91.828 |
| Display Name | Jazz Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,787,200 |
| Earnings Call Timestamp Start | 1,785,787,200 |
| Earnings Timestamp | 1,785,787,200 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 1,927,067,008 |
| Ebitda Margins | 0.41881 |
| Enterprise To Ebitda | 8.228 |
| Enterprise To Revenue | 3.446 |
| Enterprise Value | 15,856,491,520 |
| Eps Current Year | 21.11581 |
| Eps Forward | 26.0549 |
| Eps Trailing Twelve Months | 14.59 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 239.9358 |
| Fifty Day Average Change | -29.70581 |
| Fifty Day Average Change Percent | -0.123807326 |
| Fifty Two Week Change Percent | 55.899143 |
| Fifty Two Week High | 266.38 |
| Fifty Two Week High Change | -56.15001 |
| Fifty Two Week High Change Percent | -0.21078913 |
| Fifty Two Week Low | 128.8 |
| Fifty Two Week Low Change | 81.42999 |
| Fifty Two Week Low Change Percent | 0.63222045 |
| Fifty Two Week Range | 128.8 - 266.38 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,180,704,600,000 |
| Float Shares | 62,989,860 |
| Forward Eps | 26.0549 |
| Forward P E | 8.068732 |
| Free Cashflow | 1,429,392,896 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,890 |
| Fullday Change | -4.1900024 |
| Fullday Change Percent | -1.9541099 |
| Fullday Price | 210.23 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.91353995 |
| Gross Profits | 4,203,438,080 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.029040001 |
| Held Percent Institutions | 1.0232 |
| Implied Shares Outstanding | 64,914,577 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://investor.jazzpharma.com/phoenix.zhtml?c=210227&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland. |
| Long Name | Jazz Pharmaceuticals plc |
| Market | us_market |
| Market Cap | 13,646,991,360 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_6724933 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 940,752,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 15,256,223,886 |
| Number Of Analyst Opinions | 22 |
| Open | 214.25 |
| Operating Cashflow | 1,661,073,024 |
| Operating Margins | 0.26914 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 0.96 |
| Phone | 353 1 634 7800 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 210.23 |
| Post Market Time | 1,792,184,072 |
| Previous Close | 214.42 |
| Price Eps Current Year | 9.956047 |
| Price Hint | 2 |
| Price To Book | 2.837112 |
| Price To Sales Trailing12 Months | 2.965908 |
| Profit Margins | 0.20445 |
| Quick Ratio | 1.381 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.5 |
| Region | US |
| Regular Market Change | -4.19 |
| Regular Market Change Percent | -1.95411 |
| Regular Market Day High | 214.775 |
| Regular Market Day Low | 208.185 |
| Regular Market Day Range | 208.185 - 214.775 |
| Regular Market Open | 214.25 |
| Regular Market Previous Close | 214.42 |
| Regular Market Price | 210.23 |
| Regular Market Time | 1,792,180,801 |
| Regular Market Volume | 636,693 |
| Return On Assets | 0.06862 |
| Return On Equity | 0.22114 |
| Revenue Growth | 0.155 |
| Revenue Per Share | 74.598 |
| Sand P52 Week Change | 0.13723719 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 64,914,577 |
| Shares Percent Shares Out | 0.0844 |
| Shares Short | 5,479,715 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,624,690 |
| Short Name | Jazz Pharmaceuticals plc |
| Short Percent Of Float | 0.086899996 |
| Short Ratio | 7.01 |
| Source Interval | 15 |
| Symbol | JAZZ |
| Target High Price | 337.0 |
| Target Low Price | 225.0 |
| Target Mean Price | 294.63635 |
| Target Median Price | 300.0 |
| Total Cash | 2,199,800,064 |
| Total Cash Per Share | 33.888 |
| Total Debt | 4,409,299,968 |
| Total Revenue | 4,601,286,144 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 14.59 |
| Trailing P E | 14.4091835 |
| Trailing Peg Ratio | 0.9582 |
| Triggerable | 1 |
| Two Hundred Day Average | 214.4702 |
| Two Hundred Day Average Change | -4.240204 |
| Two Hundred Day Average Change Percent | -0.019770596 |
| Type Disp | Equity |
| Volume | 636,693 |
| Website | https://www.jazzpharma.com |
| Zip | D04 E5W7 |